Individual Patient Data Meta-analysis Of Randomised Control Trials In Fluid Resuscitation
Funder
National Health and Medical Research Council
Funding Amount
$85,027.00
Summary
I am a registered nurse focused in critical care research. I have an interest in the area of fluid resuscitation. My aim is to carry out an individual patient data meta-analysis (IPDMA) on randomised controlled trials (RCTs) in fluid resuscitation. The IPDMA will consist of two of the largest critical care trials; Saline Vs Albumin fluid Evaluation (SAFE) study and the Crystalloid Vs Starch (CHEST) study, to add further evidence to the currently limited fluid resuscitation literature.
Novel Hybrid Inorganic Nanoparticles for Effective siRNA Delivery to Neurons. This project will lead to a more efficient and reliable drug delivery system to treat Huntington's disease. The insights and technology gained from this project will be directly applicable for many human diseases, both within and outside the central nervous system. This project will make a major contribution to the ARC's goal of maintaining good health and promises to significantly reduce the financial and psychologica ....Novel Hybrid Inorganic Nanoparticles for Effective siRNA Delivery to Neurons. This project will lead to a more efficient and reliable drug delivery system to treat Huntington's disease. The insights and technology gained from this project will be directly applicable for many human diseases, both within and outside the central nervous system. This project will make a major contribution to the ARC's goal of maintaining good health and promises to significantly reduce the financial and psychological burdens to patients' family and community. This project will encourage inter-disciplinary approaches to research and train highly skilled researchers both in neuroscience and nanobiotechnology to advance Australia's industrial competitiveness.Read moreRead less
New metal-molecule binding motifs for self-assembled monolayers and nanodevices. The goal of this research is to investigate technologically interesting electronic materials using new molecular assemblies. We explore their application in some fundamental components of molecular electronic systems and anticipate that knowledge gained from our investigations will have significant impact on the field of nanotechnology, especially in the area of molecular electronics. Our basic research will contrib ....New metal-molecule binding motifs for self-assembled monolayers and nanodevices. The goal of this research is to investigate technologically interesting electronic materials using new molecular assemblies. We explore their application in some fundamental components of molecular electronic systems and anticipate that knowledge gained from our investigations will have significant impact on the field of nanotechnology, especially in the area of molecular electronics. Our basic research will contribute to Australia's reputation as a source of innovative research and ideas in an area where there is growing international momentum.Read moreRead less
Next-generation Glioblastoma Multiforme Therapies Based On Multistage Delivery Nanovectors
Funder
National Health and Medical Research Council
Funding Amount
$314,644.00
Summary
Nanomedicine provides novel therapies with enhanced treatment success and reduced side effects, which improve the patient’s quality of life. Drug delivery systems that are able to treat highly drug-resistant tumours such as glioblastoma multiforme (GBM) are a key target for nanomedicine-based therapies. We will investigate a new GBM treatment by developing a multistage delivery nanovector to selectively carry and release a combination of chemical and physical therapeutics.
Preclinical Development Of A Therapeutic Anticancer Antibody To C-Met
Funder
National Health and Medical Research Council
Funding Amount
$435,530.00
Summary
Many common cancers cannot be effectively treated. A range of these cancers (e.g. gastric and lung cancer) display the molecule c-Met on their cell surface. c-Met promotes tumour growth; therefore, blocking c-Met is a promising strategy for treating these cancers. However, no antibodies or drugs that target c-Met have been licensed. The therapeutics that are being developed to target c-Met all have considerable limitations. Thus, there is an opportunity to develop a 'best-in-class' therapeutic.
Therapeutic Targeting Of MYCN Oncoprotein Stability In Neuroblastoma
Funder
National Health and Medical Research Council
Funding Amount
$590,206.00
Summary
A high level of MYCN protein is a major indicator of aggressive neuroblastoma (NB) but unfortunately there have been many barriers to the design of targeted therapies. We have identified a protein called PA2G4 which is a cofactor for MYCN in promoting cancer cell growth. We have developed a compound which inhibits PA2G4 and MYCN protein levels and reduces tumour growth. We will examine how PA2G4 cause aggressive tumour characteristics and test new methods to block PA2G4.
Antibiotic Potentiators As An Alternative Therapeutic Option For The Treatment Of Extensively Drug-resistant Gram-negative Infections
Funder
National Health and Medical Research Council
Funding Amount
$856,858.00
Summary
Antibiotic mono-therapies are increasingly ineffective for hard-to-treat bacterial infections, forcing clinicians to rely on combinations of antibiotics. Our project has identified compounds that have weak to no antimicrobial potency in their own right, yet when combined with an existing antibiotic they potentiate its activity and restore its ability to treat resistant infections. These antibiotic potentiators are exciting alternatives to current therapies with reduced risk of induced resistance
Treatments that target cancer causing genes called oncogenes have resulted in new treatment paradigms for cancer. We suggest that outcomes of patients with cancer will be further substantially improved by understanding how cancers can overcome resistance to these treatments that develops in many patients. To accelerate the adoption of these and other new treatments for cancer we will also develop new frameworks for clinical trials.
There is an unmet medical need to develop new therapies that are safer and potentially allow the treatment of a broader range of cancers. Inhibiting the immune checkpoints TIGIT and CD96 represents an opportunity that may parallel and indeed complement the activity and impact of other lymphocyte checkpoint inhibitors in human cancer (eg. PD1/PD-L1). While testing these as targets in mice we will also learn more about their ligand CD155 and their expression in human tumors.
Repulsive van der Waals forces and Brownian ratchet motors: manipulating thermal and quantum Fluctuations. A fundamental problem with miniaturizing machines and mechanical devices below the micron scale is the issue of friction and lubrication. One way to completely circumvent the need for lubrication is to use a little-studied phenomenon known as 'repulsive van der Waals forces', to create materials that fundamentally repel each other in certain fluid environments. This effect is very large at ....Repulsive van der Waals forces and Brownian ratchet motors: manipulating thermal and quantum Fluctuations. A fundamental problem with miniaturizing machines and mechanical devices below the micron scale is the issue of friction and lubrication. One way to completely circumvent the need for lubrication is to use a little-studied phenomenon known as 'repulsive van der Waals forces', to create materials that fundamentally repel each other in certain fluid environments. This effect is very large at the nanoscale and this proposal examines how such forces can be used to make 'lubricant free' motors and nanomachines. This will open up the possibility of building small and portable sensors, actuators, microfluidic devices and eventually active drug delivery systems for health applications.Read moreRead less